Clinical Impact of Upfront Dose Reduction of the First Cycle of First‐Line Treatments on Safety and Survival in Elderly Patients With Non‐Small Cell Lung Cancer
UDR as a first-line treatment was safe and could be a suitable approach for elderly patients with NSCLC. Further research is needed to evaluate the clinical outcomes in the treatment of elderly NSCLC patients.
Authors
- Takashi Nojiri (ORCID: https://orcid.org/0000-0002-7049-9877)
- Kiyotsugu Iede (ORCID: https://orcid.org/0000-0001-9366-759X)
- Utae Katsushima (ORCID: https://orcid.org/0009-0005-1314-5270)
- Masahiko Higashiyama
- Akiisa Omura (ORCID: https://orcid.org/0000-0002-2810-0922)
Institutions
- Kansai Medical University (JP)
- Osaka City General Hospital (JP)
- Higashi Osaka City General Hospital (JP)
Publication Details
- Journal
- Asia-Pacific Journal of Clinical Oncology
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1111/ajco.14203
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00